AXSM - Cash Flow Statement - Axsome Therapeutics, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015	Dec-2014	Dec-2013
OPERATING CASH FLOW
Net Income	(287.2)	(239.2)	(187.1)	(130.4)	(102.9)	(68.3)	(31.0)	(28.9)	(27.2)	(10.6)	(6.0)	(2.2)
Depreciation & Amortization	0	6.8	5.6	1.2	77.7 K	37.3 K	48.9 K	42.6 K	20.5 K	3.54 K	0	0
Deferred Income Tax	0	0	0	0	1.2	0	(2.8)	0.6	0	2.3	0	0
Stock Based Compensation	85.2	62.6	37.7	20.8	14.8	6.1	1.8	2.1	2.0	0.8	0.4	55.3 K
Other Operating Activities	39.7	53.1	3.7	(0.1)	8.0	0.6	0.4	0.5	68.9 K	(0.9)	0.5	0.3
Change in Working Capital	33.9	(28.4)	23.7	0.3	0.4	15.2	1.5	(0.8)	3.8	0.9	0.5	0.2
Cash From Operations	(128.4)	(145.1)	(116.5)	(108.2)	(78.5)	(46.4)	(30.1)	(26.5)	(21.3)	(7.4)	(4.6)	(1.6)
INVESTING CASH FLOW
Capital Expenditures	(0.3)	(0.6)	(0.7)	(0.3)	45.9 K	16.1 K	32.7 K	9.9 K	(0.1)	20.2 K	0	0
Other Items	0	0	(53.0)	0	0	0	0	0	0	0	0	0
Cash From Investing Activities	(0.3)	(0.6)	(53.7)	(0.3)	45.9 K	16.1 K	32.7 K	9.9 K	(0.1)	20.2 K	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0	0	0	0	0	0	0
Total Debt Repaid	(1.0)	85.0	45.0	0	28.3	12.8	(3.3)	(0.3)	10.0	7.3	5.2	3.8
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0
Other Financing Activities	18.0	(12.7)	(4.2)	11 129 706.6	52.8 K	1.4	0.5	0.5	31.9 K	12.5 K	62.5 K	58 K
Cash From Financing Activities	57.8	331.0	284.6	11.1	42.4	252.4	10.0	23.9	10.0	52.9	5.1	3.7
CHANGE IN CASH
Net Change In Cash	(70.8)	185.4	114.4	(97.4)	(36.1)	206.0	(20.1)	(2.6)	(11.4)	45.4	0.5	2.1
FREE CASH FLOW
Free Cash Flow	(128.7)	(145.7)	(117.2)	(108.5)	(78.5)	(46.4)	(30.1)	(26.5)	(21.4)	(7.5)	(4.6)	(1.6)

Free